

## ARTICLE



## Epidemiology

# Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study

Elom K. Aglago<sup>1,2</sup>, Amanda J. Cross<sup>2</sup>, Elio Riboli<sup>2</sup>, Veronika Fedirko<sup>3,4</sup>, David J. Hughes<sup>5</sup>, Agnes Fournier<sup>6,7</sup>, Paula Jakszyn<sup>8,9</sup>, Heinz Freisling<sup>10</sup>, Marc J. Gunter<sup>1</sup>, Christina C. Dahm<sup>10</sup>, Kim Overvad<sup>10,11</sup>, Anne Tjønneland<sup>12,13</sup>, Cecilie Kyro<sup>12</sup>, Marie-Christine Boutron-Ruault<sup>6,7</sup>, Joseph A. Rothwell<sup>6,7</sup>, Gianluca Severi<sup>6,7,14</sup>, Verena Katzke<sup>15</sup>, Bernard Srour<sup>15</sup>, Matthias B. Schulze<sup>16,17</sup>, Clemens Wittenbecher<sup>16,18,19</sup>, Domenico Palli<sup>20</sup>, Sabina Sieri<sup>21</sup>, Fabrizio Pasanisi<sup>22</sup>, Rosario Tumino<sup>23</sup>, Fulvio Ricceri<sup>24,25</sup>, Bas Bueno-de-Mesquita<sup>26</sup>, Jeroen W. G. Derksen<sup>27</sup>, Guri Skeie<sup>28</sup>, Torill Enget Jensen<sup>28</sup>, Marko Lukić<sup>28</sup>, Maria-Jose Sánchez<sup>29,30,31,32</sup>, Pilar Amiano<sup>32,33,34</sup>, Sandra Colorado-Yohar<sup>32,35,36</sup>, Aurelio Barricarte<sup>32,37,38</sup>, Ulrika Ericson<sup>39</sup>, Bethany van Guelpen<sup>40</sup>, Keren Papier<sup>41</sup>, Anika Knuppel<sup>41</sup>, Corinne Casagrande<sup>1</sup>, Inge Huybrechts<sup>1</sup>, Alicia K. Heath<sup>2</sup>, Konstantinos K. Tsilidis<sup>2</sup> and Mazda Jenab<sup>1</sup>✉

© The Author(s), under exclusive licence to Springer Nature Limited 2023

**BACKGROUND:** Iron is an essential micronutrient with differing intake patterns and metabolism between men and women. Epidemiologic evidence on the association of dietary iron and its heme and non-heme components with colorectal cancer (CRC) development is inconclusive.

**METHODS:** We examined baseline dietary questionnaire-assessed intakes of total, heme, and non-heme iron and CRC risk in the EPIC cohort. Sex-specific multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were computed using Cox regression. We modelled substitution of a 1 mg/day of heme iron intake with non-heme iron using the leave one-out method.

**RESULTS:** Of 450,105 participants (318,680 women) followed for  $14.2 \pm 4.0$  years, 6162 (3511 women) developed CRC. In men, total iron intake was not associated with CRC risk (highest vs. lowest quintile,  $HR_{Q5vs.Q1}:0.88$ ; 95%CI:0.73, 1.06). An inverse association was observed for non-heme iron ( $HR_{Q5vs.Q1}:0.80$ , 95%CI:0.67, 0.96) whereas heme iron showed a non-significant association ( $HR_{Q5vs.Q1}:1.10$ ; 95%CI:0.96, 1.27). In women, CRC risk was not associated with intakes of total ( $HR_{Q5vs.Q1}:1.11$ , 95%CI:0.94, 1.31), heme ( $HR_{Q5vs.Q1}:0.95$ ; 95%CI:0.84, 1.07) or non-heme iron ( $HR_{Q5vs.Q1}:1.03$ , 95%CI:0.88, 1.20). Substitution of heme with non-heme iron demonstrated lower CRC risk in men (HR:0.94; 95%CI: 0.89, 0.99).

**CONCLUSIONS:** Our findings suggest potential sex-specific CRC risk associations for higher iron consumption that may differ by dietary sources.

*British Journal of Cancer* (2023) 128:1529–1540; <https://doi.org/10.1038/s41416-023-02164-7>

## INTRODUCTION

According to the Global Cancer Observatory (GCO), over 1.9 million new cases of colorectal cancer (CRC) were diagnosed worldwide in 2020 [1]. CRC constitutes the third most common malignancy in men and the second in women [1]. CRC etiology is multifactorial and includes established lifestyle factors such as smoking, alcohol intake, physical inactivity, or being overweight or obese [2], but also dietary factors such as higher intake of red and processed meats [2, 3].

Red meat is an important source of heme iron. Around 15–40% of heme iron is absorbed in the duodenum, leaving the remainder to proceed toward the lower gastrointestinal tract and the colorectum [4, 5]. Chemically, heme iron is in the ferrous form ( $Fe^{2+}$ ), a potent pro-oxidative form which catalyzes the Fenton reaction to produce hydroxyl free radicals evidenced to cause direct damage to DNA [6]. Heme iron is also a nitrosating agent and could contribute indirectly to increased CRC risk by

generating lipid peroxide radicals and increasing the production of carcinogenic nitrosamines in the colorectum [7, 8]. In contrast to heme iron, dietary non-heme iron originates mainly from plants and dairy products in the ferric form ( $Fe^{3+}$ ).

Despite experimental studies supporting heme iron as a possible mediating factor in the association between red and processed meats and CRC, there is limited evidence from cohort studies on the role of dietary iron, particularly comparing its heme and non-heme components. In particular, there is a need for additional evidence in men and women analyzed separately in consideration of sex-specific differences in iron intakes and metabolism across the life cycle [9]. It is known that men and women have divergent iron needs, absorption rates, turnover, and excretion in the body [10].

Eight prospective cohort studies have investigated the association between heme iron and CRC risk [11–18]. These studies, with

A full list of author affiliations appears at the end of the paper.

Received: 7 February 2022 Revised: 10 January 2023 Accepted: 13 January 2023

Published online: 9 February 2023

the exception of the most recent [18], have been included in four meta-analyses, which all showed a modest positive association (e.g., 11% higher risk for each mg higher daily intake) for heme iron and CRC risk [2, 19–21]. Among these eight studies, two reported positive associations with CRC in women [13, 22], while two others reported no statistically significant associations [12, 14]. In men, a study found a positive cancer risk association restricted to the colon [12] whereas two others found no associations [16, 17].

We addressed these questions by investigating the association between dietary total, heme, and non-heme iron intake levels and CRC risk in men and women in the European Prospective Investigation into Cancer and Nutrition (EPIC), a large multinational prospective cohort with wide variations in intake of subtypes of iron and over 6000 cases of CRC ascertained during 14.2 years of mean follow-up.

## MATERIALS AND METHODS

### Study participants

From 1992 to 2000, 521,317 participants (approximately two-thirds were women) aged between 35 and 75 years were recruited from 23 centers located in 10 European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom) [23]. Socio-demographic information, anthropometric measures, and information on diet, and other lifestyle factors were collected at baseline for all EPIC participants. Participants diagnosed with cancer prior to recruitment ( $n = 25,184$ ) were excluded from data analysis as were those lacking follow-up information ( $n = 4148$ ), lacking dietary data ( $n = 6259$ ) or those with energy intake vs. energy requirement in the extreme highest or lowest 1% ( $n = 9573$ ) (Supplementary Fig. 1). We also excluded data from participants from Greece ( $n = 26,048$ ) due to restrictions on data use and access. Ethical approval was obtained from the IARC Ethical Committee and from local ethics committees pertaining to each EPIC center. All the participants provided written informed consent to enter the cohort.

### Dietary assessment

Usual dietary intake was assessed at baseline for all the participants using country-specific validated dietary questionnaires. Dietary assessment instruments applied included self-administered quantitative food frequency questionnaires (FFQs, in the Netherlands, Germany, Greece and Italy except the center in Naples), semi-quantitative FFQs (Denmark, Norway, Naples, Umeå and, the UK), and a combination of methods such as quantitative FFQs and 1-week food records (Malmö) [24]. Food items consumed in EPIC were matched to the food composition database which was developed by the United States Department of Agriculture (USDA, Release 26 & 27) as part of the Nutrient Database for Standard Reference publications. The matching procedure has been previously described [25]. Briefly, for the estimation of dietary iron intake, the iron content of each food source, as compiled in the EPIC Nutrient Database (ENDB) matched to the USDA database, was multiplied with the individual daily intake of the food sources. To calculate heme iron intake, we applied specific coefficients based on the data from the literature: 0.65 for iron from beef, lamb and veal, 0.39 for iron from pork, 0.54 for iron from processed meats, 0.26 for iron from poultry, fish and shellfish, and 0.43 (a combined coefficient) for other meat sources of iron (including prepared foods with meats) [12, 26]. To calibrate our FFQ dietary iron data, a subsample of 5–12% of EPIC participants per center (in total, 36,000 participants) with additional baseline dietary data collected by 24 h dietary recall was used, as previously described [27]. The main dietary sources of heme iron are summarized in Supplementary Table 1. Non-heme iron intake was calculated for each participant as the difference between total iron and heme iron intake.

The Mediterranean dietary score was calculated for each participant based on the consumption of nine food items: vegetables, fruits and nuts, legumes, cereals, fish, monounsaturated fat: saturated fat ratio, dairy products, meat and poultry, and alcohol [28]. For vegetables, legumes, fruits and nuts, cereals, and fish, participants whose consumption were above the median were assigned 0, or 1 if they have intake values below the median. The score was reversed for the other food items, with the exception of ethanol consumption for which a value of 1 was assigned to men or women with consumption between 10 and 50 g/day or 5–25 g,

respectively. The sum of the scores for all the nine food groups was calculated for each participant.

### Anthropometry and lifestyle

Baseline weight and standing height were measured in all participants, except those recruited in Oxford, France, and Norway, where self-reported values were collected. Participants completed questionnaires on education, alcohol intake, smoking status, physical activity, reproductive health, and previous disease history.

### Follow-up for cancer incidence and vital status

Vital status was collected by record linkage with mortality registries in all countries except for Germany, and the Italian center of Naples, where data were collected actively. Ascertainment of incident cancer cases was undertaken through record linkage with cancer registries or a combination of health data sources including health insurance records, pathology registries, or active follow-up of the participants and their relatives. We defined CRC based on the definitions by the International Classification of Diseases for Oncology (ICD-O; codes: colon cancer: C18, and rectal cancer: C19–C20). Colon cancer included proximal colon cancers (C18.0–C18.5: cecum, appendix, ascending colon, hepatic flexure, transverse colon, and splenic flexure), distal colon cancers (C18.6–C18.7: descending colon and sigmoid colon), overlapping and unspecified (C18.8 and C18.9). Rectal cancer included incident tumors from the rectosigmoid junction down to the rectum (C19: rectosigmoid junction, C20: rectum).

### Statistical analyses

Frequencies for categorical variables and means and standard deviations for continuous variables of baseline characteristics were calculated. Cox proportional hazards regression models stratified by age at recruitment (1-year categories) were used to compute hazard ratios (HRs) and 95% confidence intervals (CI) separately for the associations between total iron, heme iron, and non-heme iron and CRC risk in men and women. Additional analyses combining men and women were also conducted. For the stratification of the models, we used the strata options in the Stcox program in STATA. This option uses the “no interaction” approach as defined by Kleinbaum and Klein [29], and computes distinct estimated hazard functions, but with similar HRs for each stratum. Time at study entry was age at recruitment, and exit time was considered as the age at whichever of the following occurred first: incident CRC diagnosis, emigration, death, or the last date at which the follow-up was considered complete (until December 2014 for the current analysis). The main analyses were run a priori separately in men and women. We ran three main models: model 1 (stratified by age at recruitment, unadjusted) and model 2 was model 1 additionally adjusted for established or putative lifestyle risk factors for CRC (excluding dietary factors): [2] body mass index (BMI, kg/m<sup>2</sup>, continuous), height (cm, continuous), physical activity (inactive, moderately inactive, moderately active, active, missing), highest education level attained (none, primary, technical/professional, secondary, higher, missing), and smoking habits and intensity (never, 1–15 cigarettes/day, 16–25 cigarettes/day, 26 or more cigarettes/day, former smokers who quit <10 years, former smokers who quit 11–20 years, former smokers who quit >20 years, current pipe-cigar and occasional smokers, missing) and total energy minus energy from alcohol (kcal/day, continuous), and energy from alcohol intake (kcal/day, continuous). Model 3 was model 2 additionally adjusted for intakes of vitamin C (mg/day, continuous), calcium (g/day, continuous), tea (g/day, continuous), and coffee (g/day, continuous) as inhibitors/enhancers of iron absorption, and for menopause status (pre-, peri-, and post-menopause) and hormone use (never, ever, unknown/missing) in women. Adjustment variables in model 3 also included cereal and cereal products, legumes, and vegetables when analyzing heme iron; and red meat, processed meats, poultry, and fish and fish products when analyzing non-heme iron. We considered model 3 as our main analysis. We also ran four intermediate models: Model S1 was adjusted for all the variables in model 2 except energy intakes variables. Because several dietary factors such as red and processed meats, or dairy products, or fish which are associated with CRC are also main sources of dietary iron [2, 3], we also used a holistic approach by adjusting for the Mediterranean dietary score as a proxy of overall dietary patterns (Model S2). In model S3, we additionally adjusted for dietary intakes of calcium, vitamin C, tea, coffee, energy from alcohol, and total energy minus energy from alcohol, and menopause status and hormone use (in women), and in model S4, we mutually adjusted for iron type i.e., heme iron analysis adjusted for non-

heme iron and vice versa. We divided intakes of total iron, heme iron and non-heme iron into country-specific quintiles. This decision was based on the observation of variation across the EPIC countries in level of iron intake (Supplementary Table 2). Trend analyses were run based on median values of each quintile. We also ran the analyses for continuous iron variables, per one standard deviation (SD) increment. In the continuous analyses, Cox regression models were additionally stratified by country in all models (including country as strata in the Cox models). No deviations from the proportional hazards assumption were observed after we assessed the proportionality using Schoenfeld residuals over time [30].

Non-linear associations were evaluated using restricted cubic splines with four knots [31]. To test the linearity of the associations, we performed likelihood ratio tests and compared for each outcome, the model with only the linear term to the model with both the linear and the cubic spline terms. We also assessed associations between the intake of types of iron and the risk by tumor anatomical subsite (colon vs. rectal cancers, and proximal vs. distal colon cancers). Differences in associations by tumor site were tested using competing risks analyses [32]. We ran Cox proportional hazards models to compute anatomical subsite-specific HRs using the duplication method [33] and further tested heterogeneity across sites (colon vs. rectal cancer and proximal colon vs. distal colon) using Wald tests. We conducted analyses stratified by menopause status (in women: premenopausal, postmenopausal, perimenopausal/unknown), and categories of age (<50, 50–<65, ≥65 years), and BMI (<25, 25–<30, ≥30 kg/m<sup>2</sup>) to investigate whether these factors which can regulate iron absorption and status may modify the risk of CRC.

**Substitution analyses.** We conducted substitution analyses to evaluate how the risk of CRC would change if replacing heme iron by non-heme iron, and vice versa [34]. We applied the leave one-out approach to calculate HRs and 95% CIs for the substitution analyses [35]. To evaluate CRC risk associated with 1 mg replacement of heme iron i.e., ~60 mg of cooked beef, with 1 mg of non-heme iron i.e., about two boiled eggs or 30 g of boiled beans, we included in multivariable-adjusted models total iron and non-heme iron, but not heme iron. Substitution models were stratified by age at recruitment and country, and adjusted for BMI, height, education, physical activity, smoking, and dietary intakes of calcium, tea, coffee, vitamin C, red meat, processed meats, poultry, and fish and fish products but not total energy intake [36]; and in women only, for menopause status and use of hormone replacement therapy. Substitution analyses assume that there is a linear association between the exposure variable and the disease risk [37], which was the case for dietary iron intake in both men and women, as observed by splines and likelihood ratio tests. Also, substitution analyses permitted us to evaluate whether the association observed could be attributed to higher/or lower intake of one specific group of iron (e.g., heme iron) while keeping tallied dietary iron from all sources unchanged [38].

**Sensitivity analyses.** To evaluate the possible impact of reverse causation, or effects of the exposure variables on tumor progression rather than initiation, all analyses were re-run excluding participants with <4 years of follow-up. We also conducted additional sensitivity analyses, by excluding participants from the UK (mostly vegetarians from the EPIC Oxford center), Italy and Spain (blood donor associations members) due to possible effects of their iron intake patterns and iron metabolism.

We considered two-sided *P* values < 0.05 as statistically significant. We corrected the *P* values obtained for multiple testing using the false discovery rate method by Benjamini-Hochberg [39]. All statistical analyses were carried out using Stata 15.1 (StataCorp, College Station, TX, USA). The figures were prepared using R software 3.5.1 (Foundation for Statistical Computing, Vienna, Austria).

## RESULTS

The final database used for statistical analyses included 450,105 participants among whom 318,680 were women (Supplementary Fig. 1). During a median follow-up of 15 years, 6162 incident CRC cases (3511 women) were identified. Table 1 summarizes the baseline characteristics of the cases and non-cases in men and women. In both men and women, cases tended to have slightly higher BMI and waist circumference; cases also had a lower education and consumed more alcohol and red and processed meats. Cases were less likely to be never smokers, consumed less calcium and were less physically active, compared to non-cases.

Total iron intake was not associated with CRC risk in men (Model 3: HR comparing the highest with the lowest quintile, HR<sub>Q5vs.Q1</sub>:0.88, 95%CI:0.73, 1.06) (Table 2). An inverse association was observed for non-heme iron intake (HR<sub>Q5vs.Q1</sub>:0.80, 95%CI:0.67, 0.96), whereas heme iron intake showed a statistically non-significant association with CRC risk (HR<sub>Q5vs.Q1</sub>:1.10, 95%CI:0.96, 1.27). In women, intakes of total iron (Model 3: HR<sub>Q5vs.Q1</sub>:1.11, 95%CI:0.94, 1.31), heme iron (HR<sub>Q5vs.Q1</sub>:0.95, 95%CI:0.84, 1.07) and non-heme iron (HR<sub>Q5vs.Q1</sub>:1.03, 95%CI:0.88, 1.20) were not associated with CRC risk. Illustrations by splines showed that CRC risk associated with total iron, heme iron, and non-heme iron were linear in men (Fig. 1). However, in women, heme iron (*P* for nonlinearity = 0.015), but not total iron (*P* for nonlinearity = 0.089), or non-heme iron (*P* for nonlinearity = 0.154) showed a non-linear association with CRC risk. After correcting for multiple testing, none of the associations remained statistically significant.

We assessed potential heterogeneity of the associations between men and women to verify whether the associations (for continuous variables) differed according to our primary hypothesis. There were no statistically significant differences between men and women in the associations between dietary heme iron (*P* for heterogeneity by sex = 0.081) or non-heme iron (*P* for heterogeneity by sex = 0.308) (Table 2).

The intermediate model (Model S1) and the model with adjustment for the Mediterranean diet (Model S2) showed similar associations to the Model 2 (Supplementary Table 3). In men, the inverse association observed for non-heme iron was stronger after adjustment for heme iron (Model S4: HR<sub>Q5vs.Q1</sub> = 0.77, 95%CI:0.64–0.92).

Analyses by tumor anatomical location (colon vs. rectum) showed that the observed associations were consistent across sub-sites for all types of iron in men (*P* value for heterogeneity: 0.274, 0.814, 0.274 for total iron, heme iron, and non-heme iron, respectively) (Table 3). There was a positive significant association observed between intakes of heme iron and rectal cancer (HR<sub>Q5vs.Q1</sub> = 1.29, 95%CI:1.03–1.61). When the associations were further examined by specific anatomical sub-divisions within the colon (proximal vs. distal), the results in men showed a statistically significant positive association in the proximal colon (HR per 1.2 mg:1.11, 95%CI:1.02, 1.20) and no association in the distal colon (HR per 1.2 mg:0.95, 95%CI:0.88, 1.04, *P* for heterogeneity = 0.008). In women, total iron, heme iron, and non-heme iron intakes showed no significant associations with CRC risk across tumor locations. Analyses combining men and women showed no significant associations between dietary total iron and non-heme iron and CRC risk (Supplementary Table 4). For both types of iron, no differences were observed in the associations by BMI categories for men and women, or by female menopausal status (Supplementary Table 5). However, we observed an inverse association between the intake of heme iron and the risk of CRC in women aged ≥65 years (*P* for heterogeneity = 0.046).

### Substitution analyses

Substitution analyses revealed that replacing 1 mg of heme iron with 1 mg of non-heme iron resulted in lower CRC risk in men (HR per 1 mg replacement:0.94, 95%CI:0.89, 0.99) (Table 4). The main benefit of the replacement was indicated by a 10% lower risk of proximal colon cancer (HR per 1 mg replacement:0.90, 95%CI:0.82, 0.99) whereas no benefit was shown for distal colon (HR per 1 mg replacement: 1.03, 95%CI: 0.93–1.14). Despite the non-linearity of the association with heme iron in women, we proceeded with the substitution analyses to provide comparability with results in men. Our analyses in women showed no apparent benefit of substituting heme iron with non-heme iron.

### Sensitivity analyses

Analyses excluding participants with <4 years of follow-up did not materially change the risk associations (Supplementary Table 6).

**Table 1.** Selected characteristics of the study population, by sex, and colorectal cancer status, EPIC cohort study, 1992–2014.

	Men		Women	
	Cases (n = 2651)	Non-cases (n = 128,774)	Cases (n = 3511)	Non-cases (315,169)
Age at recruitment, yrs	56.0 ± 7.4	51.5 ± 9.9	56.4 ± 8.1	50.1 ± 9.7
Anthropometry, mean ± SD				
BMI, kg/m <sup>2</sup>	27.2 ± 3.8	26.4 ± 3.6	25.6 ± 4.4	24.8 ± 4.3
Waist circumference, cm	97.3 ± 10.2	94.3 ± 10.1	82.3 ± 11.5	79.6 ± 11.1
Waist-to-hip ratio	0.96 ± 0.06	0.94 ± 0.06	0.81 ± 0.07	0.79 ± 0.07
Lifestyle variables, %				
Smoking status and intensity				
Never	23.9	31.7	46.7	47.1
Current	18.5	20.7	19.5	18.7
Current, 1–15 cig/day	8.6	10.0	13.0	12.4
Current, 16–25 cig/day	7.4	7.9	5.4	5.4
Current, 26+ cig/day	2.45	2.8	1.1	0.9
Former	42.1	35.2	25.4	22.5
Former, quit ≤ 10 years	13.7	12.5	8.4	8.5
Former, quit 11–20 years	13.6	11.3	7.5	7.2
Former, quit 20+ years	14.8	11.4	9.5	6.8
Current, pipe/cigar/occasional	12.1	9.3	5.67	8.7
Missing	3.5	3.1	2.63	3.2
Physical activity				
Inactive	22.4	17.5	20.3	25.6
Moderately inactive	31.2	30.9	34.3	33.8
Moderately active	21.9	24.2	27.8	23.2
Active	22.7	25.1	15.7	15.6
Missing	1.8	2.3	1.8	1.8
Highest education level attained				
None	4.5	3.2	3.9	3.5
Primary school completed	34.1	28.6	29.4	23.0
Technical/professional school	25.1	24.9	25.5	22.3
Secondary school	11.4	13.3	18.8	24.1
Higher education	21.7	27.1	16.6	23.1
Missing	3.3	2.9	5.8	4.1
Menopause				
Pre-menopause			13.4	35.0
Perimenopause			15.5	19.8
Post-menopause			67.1	42.5
Use of HRT				
Never			62.9	68.1
Ever			28.9	25.2
Missing/unknown			8.3	6.8
Dietary intake, mean ± SD				
Total energy, kcal/day	2378 ± 631	2418 ± 662	1903 ± 514	1937 ± 541
Alcohol, g/day	24.2 ± 25.1	20.9 ± 23.1	8.7 ± 12.3	8.4 ± 12
Red and processed meats, g/day	105.0 ± 59	99.0 ± 62.2	67.6 ± 40.8	66.0 ± 43.0
Poultry, g/day	22.1 ± 22.3	20.9 ± 22.0	18.0 ± 18.8	18.1 ± 18.8
Fish and shellfish, g/day	41.5 ± 36.0	37.2 ± 35.2	37.8 ± 35.1	38.2 ± 36.8
Fiber, g/day	23.5 ± 8.1	24.3 ± 8.5	22.0 ± 7.3	22.2 ± 7.4
Fat, g/day	90.4 ± 30.9	92.5 ± 32.0	73.2 ± 25.7	75.3 ± 26.6
Protein, g/day	97.5 ± 29.1	97.6 ± 30.1	81.4 ± 23.4	82.9 ± 25.1
Calcium, g/day	1.00 ± 0.4	1.04 ± 0.4	0.97 ± 0.4	0.98 ± 0.4
Tea, g/day	213 ± 201	208 ± 195	233 ± 185	221 ± 172
Coffee, g/day	485 ± 444	464 ± 429	416 ± 369	367 ± 343
Vitamin C, mg/day	110 ± 60	114 ± 63	123 ± 63	125 ± 64
Iron				
Total iron, mg/day	14.5 ± 4.7	14.6 ± 4.7	11.8 ± 3.5	12.2 ± 3.8
Heme iron, mg/day	1.9 ± 1.2	1.8 ± 1.2	1.22 ± 0.8	1.22 ± 0.8
Non heme iron, mg/day	12.6 ± 4.1	12.8 ± 4.1	10.6 ± 3.2	11.0 ± 3.4

BMI body mass index, HRT hormone replacement therapy, SD standard deviation.

**Table 2.** Hazard ratios and 95% confidence intervals for the risk of colorectal cancer associated with iron intakes, EPIC cohort study, 1992–2014.

	Quintiles of intake <sup>a</sup>					<i>P</i> <sub>trend</sub>	Continuous, per SD increment <sup>b,c</sup>
	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5		
<i>Men</i>							
Total iron							
Median intake (IQR), mg/day	9.3 (8.1; 10.2)	12.0 (11.5; 12.6)	14.1 (13.6; 14.6)	16.4 (15.8; 17.2)	20.5 (19.1; 23.0)		Per 4.7 mg
<i>n</i> cases	551	563	495	537	505		2651
Model 1	1.00 (Ref.)	0.96 (0.85, 1.08)	0.88 (0.78, 0.99)	0.95 (0.85, 1.07)	0.85 (0.75, 0.96)	0.017	0.96 (0.92, 1.00)
Model 2	1.00 (Ref.)	0.96 (0.85, 1.09)	0.87 (0.77, 1.00)	0.95 (0.82, 1.10)	0.82 (0.69, 0.98)	0.066	0.96 (0.90, 1.02)
Model 3	1.00 (Ref.)	0.98 (0.87, 1.11)	0.90 (0.79, 1.03)	0.99 (0.86, 1.15)	0.88 (0.73, 1.06)	0.317	0.96 (0.90, 1.02)
Heme iron							
Median intake (IQR), mg/day	0.51 (0.2; 0.7)	1.2 (1.0; 1.3)	1.7 (1.6; 1.8)	2.2 (2.1; 2.4)	3.2 (2.9; 3.9)		Per 1.2 mg
<i>n</i> cases	435	488	575	582	571		2651
Model 1	1.00 (Ref.)	1.09 (0.96, 1.23)	1.12 (0.99, 1.26)	1.09 (0.96, 1.24)	1.16 (1.02, 1.31)	0.040	1.05 (1.01, 1.09)
Model 2	1.00 (Ref.)	1.07 (0.95, 1.22)	1.10 (0.97, 1.25)	1.07 (0.94, 1.22)	1.13 (0.99, 1.29)	0.135	1.04 (1.00, 1.09)
Model 3	1.00 (Ref.)	1.07 (0.94, 1.21)	1.09 (0.96, 1.23)	1.05 (0.92, 1.20)	1.10 (0.96, 1.27)	0.270	1.03 (0.99, 1.08)
Non-heme iron							
Median intake (IQR), mg/day	8.1 (7.0; 8.8)	10.5 (10.0; 11.0)	12.4 (11.9; 12.8)	14.4 (13.9; 15.1)	18.1 (16.8; 20.2)		Per 4.1 mg
<i>n</i> cases	583	561	503	518	486		2651
Model 1	1.00 (Ref.)	0.93 (0.82, 1.04)	0.87 (0.78, 0.98)	0.87 (0.78, 0.98)	0.82 (0.72, 0.92)	0.001	0.94 (0.91, 0.98)
Model 2	1.00 (Ref.)	0.92 (0.82, 1.04)	0.86 (0.76, 0.99)	0.86 (0.74, 0.99)	0.78 (0.65, 0.92)	0.005	0.93 (0.88, 0.99)
Model 3	1.00 (Ref.)	0.93 (0.82, 1.05)	0.88 (0.77, 1.00)	0.88 (0.76, 1.01)	0.80 (0.67, 0.96)	0.019	0.94 (0.89, 1.00)
<i>Women</i>							
Total iron							
Median intake (IQR), mg/day	7.8 (6.9; 8.5)	10.1 (9.6; 10.5)	11.8 (11.4; 12.2)	13.7 (13.2; 14.3)	17.1 (15.9; 19.0)		Per 3.8 mg
<i>n</i> cases	758	726	762	704	561		3511
Model 1	1.00 (Ref.)	1.00 (0.90, 1.11)	1.03 (0.93, 1.14)	1.10 (0.99, 1.22)	0.95 (0.85, 1.06)	0.919	0.99 (0.96, 1.03)
Model 2	1.00 (Ref.)	1.02 (0.92, 1.14)	1.07 (0.96, 1.20)	1.17 (1.03, 1.32)	1.03 (0.89, 1.20)	0.156	1.02 (0.97, 1.07)
Model 3	1.00 (Ref.)	1.04 (0.93, 1.16)	1.11 (0.98, 1.25)	1.22 (1.07, 1.40)	1.11 (0.94, 1.31)	0.025	1.02 (0.97, 1.07)
Heme iron							
Median intake (IQR), mg/day	0.3 (0.1; 0.4)	0.75 (0.7; 0.8)	1.1 (1.0; 1.2)	1.5 (1.4; 1.6)	2.2 (2.0; 2.7)		Per 0.8 mg
<i>n</i> cases	608	719	789	771	624		3511
Model 1	1.00 (Ref.)	1.03 (0.92, 1.14)	1.02 (0.92, 1.14)	1.07 (0.97, 1.19)	1.02 (0.92, 1.14)	0.457	1.01 (0.97, 1.04)
Model 2	1.00 (Ref.)	1.02 (0.92, 1.14)	1.01 (0.90, 1.12)	1.06 (0.95, 1.18)	1.00 (0.89, 1.12)	0.743	1.00 (0.96, 1.04)
Model 3	1.00 (Ref.)	1.00 (0.90, 1.12)	0.98 (0.88, 1.09)	1.01 (0.91, 1.13)	0.95 (0.84, 1.07)	0.504	0.98 (0.95, 1.02)

Table 2. continued

	Quintiles of intake <sup>a</sup>					P <sub>trend</sub>	Continuous, per SD increment <sup>b,c</sup>
	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5		
Non heme iron							
Median intake (IQR), mg/day	7.0 (6.1; 7.6)	9.0 (8.6; 9.4)	10.6 (10.2; 11.0)	12.4 (11.9; 12.9)	15.4 (14.4; 17.1)		Per 3.4 mg
n cases	775	757	706	713	560		3511
Model 1	1.00 (Ref.)	0.98 (0.89, 1.09)	1.04 (0.94, 1.15)	1.06 (0.96, 1.18)	0.93 (0.84, 1.04)	0.710	0.99 (0.96, 1.02)
Model 2	1.00 (Ref.)	1.01 (0.90, 1.12)	1.08 (0.96, 1.21)	1.12 (0.99, 1.27)	1.00 (0.86, 1.17)	0.344	1.02 (0.97, 1.07)
Model 3	1.00 (Ref.)	1.01 (0.91, 1.13)	1.09 (0.97, 1.23)	1.14 (1.01, 1.30)	1.03 (0.88, 1.20)	0.209	1.03 (0.98, 1.09)

IQR interquartile range.

<sup>a</sup>The analyses were run using country-specific quintiles.

<sup>b</sup>For the continuous analysis, all the models were adjusted for the same variables as the in quintiles analysis, but with additional stratification by country.

<sup>c</sup>P values for heterogeneity by sex (using continuous values) for total iron, heme iron, and non-heme iron, respectively, were for Model 1, 0.124, 0.260 and 0.031; and Model 2, 0.528, 0.091, and 0.176; and Model 3, 0.802, 0.081, 0.308.

Model 1 was stratified by age at recruitment.

Model 2 was model 1 additionally adjusted for BMI, height, education, physical activity, smoking, energy intakes from alcohol, and total energy minus energy from alcohol.

Model 3 was model 2 additionally adjusted for intakes of vitamin C, calcium, tea, coffee, and in women specifically menopause status and hormone use. Model 3 for heme iron additionally included intakes of cereal, and cereal products, legumes, and vegetables whereas model 3 for non-heme iron included intakes of red meat, processed meats, poultry, and fish and fish products.

In addition, excluding participants from Italy and Spain (blood donors), or UK (health-conscious) from the regression models did not materially change the findings.


## DISCUSSION

In this large prospective cohort study, we found that higher intake of non-heme iron was inversely associated with CRC risk in men. Analyses by anatomical sub-site suggested a stronger positive association with heme iron in the proximal colon vs. the distal colon, while no difference in the risk association was observed between the colon and rectum. In women, higher consumption of total iron, heme iron, and non-heme iron was not associated with CRC risk. Substitution of heme with non-heme iron (per 1 mg replacement) was associated with a 6% lower risk in men and had no observable projected association in women.

Previous prospective studies have mostly examined CRC associations with iron intake in women [11–14, 17] and only a few studies presented data for both men and women [12, 16] or in sex-adjusted analyses of men and women combined [15, 18]. Similar to our results, most of these studies did not find an association between heme iron intake and CRC risk in women [12, 14, 16, 17]. Two studies found higher risk of CRC associated with heme iron intake in women [11, 13]. However, there are no previous prospective studies regarding the non-heme iron-CRC risk association. The only information to date derives from case-control studies, which show either an inverse [40] or null association [41]. In women, iron absorption may decrease after menopause due to natural amenorrhea [42]. Hypothetically, postmenopausal women may have higher levels of iron reaching the colon conferring an increased CRC risk, compared to pre-menopausal women. However, we did not observe a difference between pre- and post-menopausal women, although we observed that among women  $\geq 65$  years, higher heme iron intake was inversely associated with CRC risk.

The dissimilar associations observed between heme and non-heme iron in men could be due to multiple factors. First, the positive association between higher heme iron intake and the risk of proximal colon cancer observed in men could be explained by higher intakes and concentration of iron reaching the colon, considering the lower rate of absorption of iron in men compared to women [43]. Iron pool in the body is efficiently conserved and recycled in humans, as minor losses only occur with the death and removal of skin cells, and minor losses from the renewal of gastrointestinal tissues [44]. Non-heme iron is principally different from heme iron as it originates mainly from plant foods and does not promote the synthesis of nitrosamines. Non-heme iron is easily chelated by antinutrients and participates in fewer reactions within the gastrointestinal tract, compared to heme iron. Animal studies have shown that non-heme iron is absorbed throughout the gastrointestinal tract, mostly in the duodenum, but also in the colon [45, 46]. Sesink et al. [47] have reported that adding heme, an iron-containing breakdown product of hemoglobin, to the diet of rats promotes colonic epithelial proliferation whereas non-heme iron did not. Nonetheless, there is a need for future studies to investigate the potential inverse association observed with non-heme iron in men. Interestingly, our substitution analyses found that replacing 1 mg of daily heme iron intake with an equivalent daily amount of non-heme iron was associated with 6% lower risk of CRC in men. Although a 6% reduction of CRC risk (10% for proximal colon cancer risk) associated with replacement of 1 mg of heme iron with 1 mg of non-heme iron may seem large, it is plausible and corresponds to the risk observed in low-meat eaters compared to regular meat eaters [48]. Thus, our findings provide additional evidence that it might be the amount of heme iron, not non-heme iron, in the diet that is associated with an increased CRC risk.

There is no clear explanation of the differences in the association of disease risk by tumor anatomical subsite, particularly in the colon.



**Fig. 1 Splines of the associations between dietary iron intake and colorectal risk in men and women.** Splines models were adjusted for body mass index, height, education, physical activity, smoking, and for energy intakes from alcohol, and total energy minus energy from alcohol, intakes of vitamin C, calcium, tea, coffee, and stratified by age at recruitment and country. In women specifically menopause status and hormone use were included in the model. For heme iron, additional confounders included intakes of cereal, and cereal products, legumes, and vegetables whereas for non-heme iron it included intakes of red meat, processed meats, poultry, and fish and fish products for non-heme iron. The median intake values of the lowest quintiles were used as the reference. Deviations from linearity were tested using likelihood ratio tests comparing the model with only the linear term to the model with both the linear and the cubic spline terms. The grayish area represents the 95% confidence intervals.

One plausible explanation may be the actions of the microbiome and their interactions with iron available in the colon. The microbiome is profoundly influenced by the availability of iron, and iron is important for the growth and functions of bacteria in the colon, but higher levels of heme essentially promote the growth of pathogenic bacteria [49]. Thus, heme iron-depleted conditions evaluated with a heme-deficient culture medium limit the growth of pathogenic bacteria such as *Salmonella typhimurium* and *Escherichia coli*, while it has no effect on other bacteria such as *Lactobacillus* [49]. The mutagenic actions of deleterious bacteria is likely to occur in the proximal colon because its protective mucus barrier is thinner compared to the mucus barrier in the distal colon [50]. Nevertheless, we cannot rule out a possible chance finding as heme iron intake was associated with higher rectal cancer risk as

well. It is highly likely that the production of nitrosamines is an important factor in CRC development. The center of the heme molecule, where the iron is located, can convert nitrite into nitric acid and higher intake of red meat has been shown to increase levels of O<sup>6</sup>-methyl-2-deoxyguanosine (O<sup>6</sup>MeG), a DNA adduct derived from nitrosamines in the distal colon [51]. Importantly O<sup>6</sup>MeG has been found in human rectal biopsies [52] as an endpoint to the cumulated production of nitrosamines throughout the colon. It is therefore possible that the mutagenic actions of nitrosamines may be enhanced in the rectum. This could explain the higher risk of rectal cancer observed with heme iron in our study. Similarly, it is intriguing that we observed an inverse association between dietary heme iron intake and CRC risk in women aged beyond 65 years. This could be the combined effects of lifestyle changes with age toward

**Table 3.** Hazard ratios and 95% confidence intervals for iron intake and the risk of colorectal cancer by anatomical subsites, EPIC cohort study, 1992–2014.

	Quintiles of intake <sup>a</sup>					<i>P</i> <sub>trend</sub>	Continuous, per SD increment <sup>b,c,d</sup>
	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5		
<i>Men</i>							
<i>Total iron</i>							
Median intake (IQR), mg/day	9.3 (8.1; 10.2)	12.0 (11.5; 12.6)	14.1 (13.6; 14.6)	16.4 (15.8; 17.2)	20.5 (19.1; 23.0)		Per 4.7 mg
<i>Colon cancer</i>							
<i>n</i> cases	351	321	304	336	282		1594
HR (95%CI)	1.00 (Ref.)	0.91 (0.78, 1.06)	0.83 (0.70, 0.99)	0.92 (0.76, 1.11)	0.75 (0.60, 0.95)	0.059	0.95 (0.88, 1.03)
<i>Proximal colon cancer</i>							
<i>n</i> cases	137	128	125	147	122		659
HR (95%CI)	1.00 (Ref.)	0.94 (0.73, 1.20)	0.91 (0.69, 1.19)	1.08 (0.81, 1.45)	0.92 (0.65, 1.31)	0.922	1.04 (0.92, 1.17)
<i>Distal colon cancer</i>							
<i>n</i> cases	175	149	150	159	124		757
HR (95%CI)	1.00 (Ref.)	0.85 (0.68, 1.07)	0.82 (0.64, 1.05)	0.86 (0.66, 1.12)	0.63 (0.45, 0.88)	0.036	0.91 (0.81, 1.02)
<i>Rectal cancer</i>							
<i>n</i> cases	215	224	206	214	198		1057
HR (95%CI)	1.00 (Ref.)	1.06 (0.87, 1.28)	0.95 (0.77, 1.18)	1.01 (0.80, 1.27)	0.94 (0.71, 1.25)	0.634	0.97 (0.88, 1.07)
<i>Heme iron</i>							
Median intake (IQR), mg/day	0.51 (0.2; 0.7)	1.2 (1.0; 1.3)	1.7 (1.6; 1.8)	2.2 (2.1; 2.4)	3.2 (2.9; 3.9)		Per 1.2 mg
<i>Colon cancer</i>							
<i>n</i> cases	286	323	346	319	320		1594
HR (95%CI)	1.00 (Ref.)	1.03 (0.87, 1.21)	1.03 (0.87, 1.21)	0.98 (0.83, 1.16)	1.00 (0.83, 1.19)	0.783	1.03 (0.97, 1.09)
<i>Proximal colon cancer</i>							
<i>n</i> cases	111	120	146	156	126		659
HR (95%CI)	1.00 (Ref.)	0.97 (0.74, 1.25)	1.09 (0.84, 1.40)	1.22 (0.94, 1.57)	1.00 (0.75, 1.33)	0.414	1.11 (1.02, 1.20)
<i>Distal colon cancer</i>							
<i>n</i> cases	139	158	166	140	154		757
HR (95%CI)	1.00 (Ref.)	1.05 (0.83, 1.33)	1.04 (0.82, 1.31)	0.89 (0.70, 1.14)	0.99 (0.77, 1.29)	0.525	0.95 (0.88, 1.04)
<i>Rectal cancer</i>							
<i>n</i> cases	169	209	231	218	230		1057
HR (95%CI)	1.00 (Ref.)	1.13 (0.92, 1.39)	1.20 (0.97, 1.47)	1.18 (0.95, 1.45)	1.29 (1.03, 1.61)	0.036	1.05 (0.98, 1.12)
<i>Non-heme iron</i>							
Median intake (IQR), mg/day	8.1 (7.0; 8.8)	10.5 (10.0; 11.0)	12.4 (11.9; 12.8)	14.4 (13.9; 15.1)	18.1 (16.8; 20.2)		Per 4.1 mg
<i>Colon cancer</i>							
<i>n</i> cases	366	316	309	319	284		1594
HR (95%CI)	1.00 (Ref.)	0.86 (0.74, 1.01)	0.82 (0.69, 0.97)	0.84 (0.69, 1.01)	0.73 (0.58, 0.92)	0.018	0.94 (0.86, 1.01)
<i>Proximal colon cancer</i>							
<i>n</i> cases	142	135	122	132	128		659
HR (95%CI)	1.00 (Ref.)	0.96 (0.75, 1.23)	0.86 (0.65, 1.12)	0.94 (0.70, 1.26)	0.94 (0.66, 1.33)	0.680	0.98 (0.87, 1.12)
<i>Distal colon cancer</i>							
<i>n</i> cases	182	145	153	151	126		757
HR (95%CI)	1.00 (Ref.)	0.80 (0.64, 1.01)	0.81 (0.64, 1.04)	0.79 (0.60, 1.03)	0.62 (0.45, 0.87)	0.021	0.92 (0.82, 1.04)
<i>Rectal cancer</i>							
<i>n</i> cases	218	226	214	203	196		1057
HR (95%CI)	1.00 (Ref.)	1.05 (0.86, 1.28)	0.98 (0.80, 1.22)	0.95 (0.75, 1.19)	0.93 (0.70, 1.23)	0.419	0.96 (0.87, 1.06)
<i>Women</i>							
<i>Total iron</i>							
Median intake (IQR), mg/day	7.8 (6.9; 8.5)	10.1 (9.6; 10.5)	11.8 (11.4; 12.2)	13.7 (13.2; 14.3)	17.1 (15.9; 19.0)		Per 3.8 mg
<i>Colon cancer</i>							
<i>n</i> cases	495	465	491	527	425		2403
HR (95%CI)	1.00 (Ref.)	0.97 (0.85, 1.11)	1.06 (0.92, 1.22)	1.19 (1.02, 1.39)	1.03 (0.85, 1.24)	0.138	1.02 (0.96, 1.09)
<i>Proximal colon cancer</i>							
<i>n</i> cases	244	251	237	258	207		1197
HR (95%CI)	1.00 (Ref.)	1.05 (0.87, 1.26)	1.01 (0.83, 1.23)	1.13 (0.91, 1.41)	0.95 (0.73, 1.25)	0.878	1.01 (0.92, 1.10)



Table 3. continued

	Quintiles of intake <sup>a</sup>					<i>P</i> <sub>trend</sub>	Continuous, per SD increment <sup>b,c,d</sup>
	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5		
Distal colon cancer							
<i>n</i> cases	209	169	210	214	167		969
HR (95%CI)	1.00 (Ref.)	0.85 (0.69, 1.05)	1.11 (0.90, 1.38)	1.20 (0.94, 1.52)	1.02 (0.76, 1.37)	0.166	1.05 (0.95, 1.16)
Rectal cancer							
<i>n</i> cases	192	226	211	214	203		1046
HR (95%CI)	1.00 (Ref.)	1.14 (0.93, 1.38)	1.10 (0.89, 1.36)	1.13 (0.90, 1.42)	1.06 (0.80, 1.39)	0.710	1.02 (0.93, 1.12)
Heme iron							
Median intake (IQR), mg/day	0.3 (0.1; 0.4)	0.75 (0.7; 0.8)	1.1 (1.0; 1.2)	1.5 (1.4; 1.6)	2.2 (2.0; 2.7)		Per 0.8 mg
Colon cancer							
<i>n</i> cases	446	479	506	498	474		2403
HR (95%CI)	1.00 (Ref.)	1.05 (0.93, 1.20)	1.02 (0.90, 1.17)	1.03 (0.90, 1.17)	0.99 (0.86, 1.14)	0.774	0.99 (0.94, 1.03)
Proximal colon cancer							
<i>n</i> cases	232	242	249	245	229		1197
HR (95%CI)	1.00 (Ref.)	1.02 (0.85, 1.22)	0.94 (0.78, 1.13)	0.95 (0.78, 1.15)	0.89 (0.73, 1.09)	0.208	0.95 (0.89, 1.01)
Distal colon cancer							
<i>n</i> cases	174	196	210	197	192		969
HR (95%CI)	1.00 (Ref.)	1.13 (0.92, 1.38)	1.14 (0.93, 1.40)	1.10 (0.89, 1.36)	1.10 (0.88, 1.39)	0.515	1.02 (0.95, 1.09)
Rectal cancer							
<i>n</i> cases	202	194	209	233	208		1046
HR (95%CI)	1.00 (Ref.)	0.90 (0.74, 1.10)	0.89 (0.73, 1.08)	0.99 (0.81, 1.20)	0.87 (0.71, 1.07)	0.475	0.97 (0.91, 1.04)
Non-heme iron							
Median intake (IQR), mg/day	7.0 (6.1; 7.6)	9.0 (8.6; 9.4)	10.6 (10.2; 11.0)	12.4 (11.9; 12.9)	15.4 (14.4; 17.1)		Per 3.4 mg
Colon cancer							
<i>n</i> cases	503	455	512	510	423		2403
HR (95%CI)	1.00 (Ref.)	0.95 (0.83, 1.08)	1.10 (0.96, 1.26)	1.14 (0.98, 1.33)	1.01 (0.83, 1.22)	0.226	1.03 (0.96, 1.10)
Proximal colon cancer							
<i>n</i> cases	241	245	257	243	211		1197
HR (95%CI)	1.00 (Ref.)	1.06 (0.88, 1.28)	1.15 (0.94, 1.40)	1.12 (0.90, 1.40)	1.04 (0.79, 1.36)	0.591	1.03 (0.94, 1.13)
Distal colon cancer							
<i>n</i> cases	213	170	207	214	165		969
HR (95%CI)	1.00 (Ref.)	0.84 (0.68, 1.04)	1.06 (0.86, 1.32)	1.16 (0.91, 1.47)	0.97 (0.72, 1.31)	0.308	1.05 (0.94, 1.16)
Rectal cancer							
<i>n</i> cases	208	239	220	231	210		1108
HR (95%CI)	1.00 (Ref.)	1.17 (0.96, 1.42)	1.09 (0.88, 1.35)	1.16 (0.93, 1.46)	1.08 (0.82, 1.43)	0.627	1.04 (0.94, 1.14)

IQR interquartile range.

<sup>a</sup>The analyses were run using country-specific quintiles.

<sup>b</sup>For the continuous analysis, all the models were adjusted for the same variables as the in quintiles analysis, but with additional stratification by country.

<sup>c</sup>*P* values for heterogeneity by sex (using continuous values) for total iron, heme iron, and non-heme iron, respectively, were for all colon cancer, 0.994, 0.181, 0.573; proximal colon cancer 0.453, 0.004, 0.779; distal colon cancer, 0.505, 0.384, 0.665; rectal cancer, 0.691, 0.275, 0.352.

<sup>d</sup>In men, *P* for heterogeneity colon vs. rectal cancer were 0.274, 0.814, 0.274 for total iron, heme iron, and non-heme iron, respectively; and *P* for heterogeneity proximal colon cancer vs. distal colon cancer were 0.129, 0.008, 0.448 for total iron, heme iron, and non-heme iron, respectively. In women, *P* for heterogeneity colon vs. rectal cancer were 0.999, 0.579, 0.999 for total iron, heme iron, and non-heme iron, respectively; and *P* for heterogeneity proximal colon cancer vs. distal colon cancer were 0.671, 0.162, 0.999 for total iron, heme iron, and non-heme iron, respectively.

There were 178 and 239 overlapping and non-specified colon or rectal cancer cases in men and women, respectively.

Models were adjusted for BMI, height, education, physical activity, smoking, energy intakes from alcohol, and total energy minus energy from alcohol, intakes of vitamin C, calcium, tea, coffee, and stratified by age at recruitment. In women specifically menopause status and hormone use were included in the model. For heme iron, additional confounders included intakes of cereal, and cereal products, legumes, and vegetables whereas for non-heme iron it included intakes of red meat, processed meats, poultry, and fish and fish products for non-heme iron.

healthier behaviors such as leisure physical activity practice, smoking cessation, or reduction in drinking intensity. Another conceivable hypothesis may be the well-documented significant changes in the microbiome of older subjects, with abundance of short-chain fatty acids producing genera such as *Collinsella* [53]. There is a need to further investigate the potential effects and mechanisms of heme iron in the proximal colon vs. distal colon, and in elderly women.

Strengths of our study include its prospective study design and large population. Our study is mainly limited by the single collection

of dietary intakes at baseline, and the absence of data on iron supplements intake in the population, although supplement intake has been reported to be recurrent and variable between countries [54]. Absence of data on gastrointestinal conditions such as inflammatory bowel diseases is another limitation in our study. Also, it is possible that some of our results may be due to residual confounding despite comprehensive adjustment for covariates and extended sensitivity analyses. Noteworthy, because our study was based on dietary iron, and did not consider iron absorption, our findings could not be interpreted in parallel with body iron status. In

**Table 4.** Hazard ratios and 95% confidence intervals for substituting dietary heme iron (1 mg) with non-heme iron.

	Men	Women
Colorectal cancer	0.94 (0.89, 0.99)	1.01 (0.96, 1.07)
Colon cancer	0.95 (0.89, 1.02)	1.01 (0.94, 1.08)
Proximal colon cancer	0.90 (0.82, 0.99)	1.08 (0.98, 1.19)
Distal colon cancer	1.03 (0.93, 1.14)	0.98 (0.88, 1.09)
Rectal cancer	0.92 (0.85, 1.00)	1.01 (0.92, 1.12)

Models were adjusted for BMI, height, education, physical activity, smoking, and dietary intakes of calcium, tea, coffee, vitamin C, red meat, processed meats, poultry, and fish and fish product and particularly in women for menopause status and use of hormone replacement therapy.

In addition, our analyses did not adjust for family history of CRC, or for anti-nutrients such as phytic acid and oxalates which inhibit iron absorption, due to unavailability of these variables in our cohort. Other limitations include recall and measurements errors (both for lifestyle and dietary intake), and difficulty in comparing country-specific dietary questionnaires. Finally, our findings may not be generalizable to other settings where iron intakes are low, or where varying intakes of vitamin C (promotes non-heme iron absorption), dietary iron chelators (bind and inhibit iron action and absorption) or recurrent infections affect iron transit and absorption.

In conclusion, we found that dietary non-heme iron was inversely associated with the risk of CRC in men whereas heme iron intake showed a positive association restricted to the proximal colon. No significant associations were observed between intake of total or different types of iron and CRC risk in women. Our findings suggest that any CRC risk associations for higher dietary iron are likely to be sex-specific and may vary between its heme- and non-heme components. Additional research, looking at body iron status and metabolism may shed some more light on this important question. Moreover, evidence on the link between iron and CRC is required from other non-European populations with different intake levels, and behaviors that may promote or inhibit iron absorption and utilization.

## DISCLAIMER

Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this paper and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.

## DATA AVAILABILITY

For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at <http://epic.iarc.fr/access/index.php>.

## REFERENCES

- Global Cancer Observatory-Cancer today [Internet]. IARC-WHO. 2020 [cited 22/12/2020]. <https://gco.iarc.fr/today/home>.
- WCRF. Diet, Nutrition, Physical Activity and Colorectal Cancer. London, UK: World Cancer Research Fund; 2018.
- Bouvard V, Loomis D, Guyton KZ, Grosse Y, Ghisssani FE, Benbrahim-Tallaa L, et al. Carcinogenicity of consumption of red and processed meat. *Lancet Oncol*. 2015;16:1599–600.
- Hallberg L, Hultén L, Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? *Am J Clin Nutr*. 1997;66:347–56.
- Ishikawa S, Tamaki S, Ohata M, Arihara K, Itoh M. Heme induces DNA damage and hyperproliferation of colonic epithelial cells via hydrogen peroxide produced by

- heme oxygenase: a possible mechanism of heme-induced colon cancer. *Mol Nutr Food Res*. 2010;54:1182–91.
- Glei M, Klenow S, Sauer J, Wegewitz U, Richter K, Pool-Zobel BL. Hemoglobin and heme induce DNA damage in human colon tumor cells HT29 clone 19A and in primary human colonocytes. *Mutat Res*. 2006;594:162–71.
  - Lunn JC, Kuhnlé G, Mai V, Frankenfeld C, Shuker DE, Glen RC, et al. The effect of haem in red and processed meat on the endogenous formation of N-nitroso compounds in the upper gastrointestinal tract. *Carcinogenesis* 2007;28:685–90.
  - Cross AJ, Pollock JRA, Bingham SA. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. *Cancer Res*. 2003;63:2358–60.
  - Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. *J Res Med Sci: Off J Isfahan Univ Med Sci*. 2014;19:164–74.
  - Hunt JR, Zito CA, Johnson LK. Body iron excretion by healthy men and women. *Am J Clin Nutr*. 2009;89:1792–8.
  - Lee DH, Anderson KE, Folsom AR, Jacobs DR Jr. Heme iron, zinc and upper digestive tract cancer: the Iowa Women's Health Study. *Int J Cancer*. 2005;117:643–7.
  - Balder HF, Vogel J, Jansen MC, Weijenberg MP, van den Brandt PA, Westenberg S, et al. Heme and chlorophyll intake and risk of colorectal cancer in the Netherlands cohort study. *Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Preventive Oncol*. 2006;15:717–25.
  - Larsson SC, Adami H-O, Giovannucci E, Wolk A. Re: Heme Iron, Zinc, Alcohol Consumption, and Risk of Colon Cancer. *J Natl Cancer Inst*. 2005;97:232–3.
  - Kabat GC, Miller AB, Jain M, Rohan TE. A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. *Br J Cancer*. 2007;97:118–22.
  - Cross AJ, Ferrucci LM, Risch A, Graubard BI, Ward MH, Park Y, et al. A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. *Cancer Res*. 2010;70:2406–14.
  - Zhang X, Giovannucci EL, Smith-Warner SA, Wu K, Fuchs CS, Pollak M, et al. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. *Cancer Causes Control*. 2011;22:1627–37.
  - Hara A, Sasazuki S, Inoue M, Iwasaki M, Shimazu T, Sawada N, et al. Zinc and heme iron intakes and risk of colorectal cancer: a population-based prospective cohort study in Japan. *Am J Clin Nutr*. 2012;96:864–73.
  - Etemadi A, Abnet CC, Graubard BI, Beane-Freeman L, Freedman ND, Liao L, et al. Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: Findings from three large US cohorts. *Int J Cancer*. 2018;143:2261–70.
  - Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk—a systematic review and meta-analysis of the epidemiological evidence. *Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Preventive Oncol*. 2014;23:12–31.
  - Qiao L, Feng Y. Intakes of heme iron and zinc and colorectal cancer incidence: a meta-analysis of prospective studies. *Cancer Causes Control*. 2013;24:1175–83.
  - Bastide N, Pierre F, Corpet D. Heme Iron from Meat and Risk of Colorectal Cancer: A Meta-analysis and a Review of the Mechanisms Involved. *Cancer Prev Res (Phila, Pa)*. 2011;4:177–84.
  - Lee DH, Anderson KE, Harnack LJ, Folsom AR, Jacobs DR Jr. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. *J Natl Cancer Inst*. 2004;96:403–7.
  - Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr*. 2002;5:1113–24.
  - Gonzalez CA. The European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutr*. 2006;9:124–6.
  - Van Puyvelde H, Perez-Cornago A, Casagrande C, Nicolas G, Versele V, Skeie G, et al. Comparing Calculated Nutrient Intakes Using Different Food Composition Databases: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. *Nutrients* 2020;12:2906.
  - Cross AJ, Harnly JM, Ferrucci LM, Risch A, Mayne ST, Sinha R. Developing a heme iron database for meats according to meat type, cooking method and doneness level. *Food Nutr Sci*. 2012;3:905–13.
  - Jakszyn P, Agudo A, Lujan-Barroso L, Bueno-de-Mesquita HB, Jenab M, Navarro C, et al. Dietary intake of heme iron and risk of gastric cancer in the European prospective investigation into cancer and nutrition study. *Int J Cancer*. 2012;130:2654–63.
  - Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. *N Engl J Med*. 2003;348:2599–608.
  - Kleinbaum D, Klein M. *Survival Analysis: A Self-Learning Text*. 1. NY, USA: Springer; 2005. p. 700.
  - Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in cox regression. *Stat Med*. 1995;14:1707–23.
  - Harrell FEJ. [Internet]. Rms: Regression Modeling Strategies. R package version 6.3-0 [cited 31/12/2016]. <https://CRAN.R-project.org/package=rms>.
  - Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. *Bone Marrow Transpl*. 2007;40:381–7.

33. Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al. Statistical methods for studying disease subtype heterogeneity. *Stat Med.* 2016;35:782–800.
34. Ibsen DB, Laursen ASD, Würztz AML, Dahm CC, Rimm EB, Parner ET, et al. Food substitution models for nutritional epidemiology. *Am J Clin Nutr.* 2021;113:294–303.
35. Song M, Giovannucci E. Substitution analysis in nutritional epidemiology: proceed with caution. *Eur J Epidemiol.* 2018;33:137–40.
36. Tomova GD, Gilthorpe MS, Tennant PWG. Theory and performance of substitution models for estimating relative causal effects in nutritional epidemiology. *Am J Clin Nutr.* 2022;116:1379–88.
37. van den Brandt PA. Red meat, processed meat, and other dietary protein sources and risk of overall and cause-specific mortality in The Netherlands Cohort Study. *Eur J Epidemiol.* 2019;34:351–69.
38. Alferink LJ, Kieft-de Jong JC, Erler NS, Veldt BJ, Schoufour JD, de Knecht RJ, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. *Gut* 2019;68:1088–98.
39. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B (Methodol).* 1995;57:289–300.
40. Ronco A, Calderon J, Mendoza B, Espinosa E, Lasalvia-Galante E. Dietary Iron Sources and Colorectal Cancer Risk: A Role for Sex. *Journal of Cancer Science and Treatment.* 2019;93–110.
41. Luo H, Zhang NQ, Huang J, Zhang X, Feng XL, Pan ZZ, et al. Different forms and sources of iron in relation to colorectal cancer risk: a case-control study in China. *Br J Nutr.* 2019;121:735–47.
42. Fairweather-Tait SJ, Jennings A, Harvey LJ, Berry R, Walton J, Dainty JR. Modeling tool for calculating dietary iron bioavailability in iron-sufficient adults. *Am J Clin Nutr.* 2017;105:1408–14.
43. Woodhead JC, Drulis JM, Nelson SE, Janghorbani M, Fomon SJ. Gender-Related Differences in Iron Absorption by Preadolescent Children. *Pediatr Res.* 1991;29:435–9.
44. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. *Int J Biochem Cell Biol.* 2001;33:940–59.
45. Johnston KL, Johnson DM, Marks J, Srai SK, Debnam ES, Sharp PA. Non-haem iron transport in the rat proximal colon. *Eur J Clin Invest.* 2006;36:35–40.
46. Takeuchi K, Bjarnason I, Laftah AH, Latunde-Dada GO, Simpson RJ, McKie AT. Expression of iron absorption genes in mouse large intestine. *Scand J Gastroenterol.* 2005;40:169–77.
47. Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R. Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. *Cancer Res.* 1999;59:5704–9.
48. Watling CZ, Schmidt JA, Dunneram Y, Tong TYN, Kelly RK, Knuppel A, et al. Risk of cancer in regular and low meat-eaters, fish-eaters, and vegetarians: a prospective analysis of UK Biobank participants. *BMC Med.* 2022;20:73.
49. Parmanand BA, Kellingray L, Le Gall G, Basit AW, Fairweather-Tait S, Narbad A. A decrease in iron availability to human gut microbiome reduces the growth of potentially pathogenic gut bacteria; an in vitro colonic fermentation study. *J Nutr Biochem.* 2019;67:20–7.
50. Kamphuis JBJ, Mercier-Bonin M, Eutamène H, Theodorou V. Mucus organisation is shaped by colonic content; a new view. *Sci Rep.* 2017;7:8527.
51. Winter J, Nyskohus L, Young GP, Hu Y, Conlon MA, Bird AR, et al. Inhibition by resistant starch of red meat-induced promutagenic adducts in mouse colon. *Cancer Prev Res (Philo).* 2011;4:1920–8.
52. Le Leu RK, Winter JM, Christophersen CT, Young GP, Humphreys KJ, Hu Y, et al. Butyrylated starch intake can prevent red meat-induced O6-methyl-2-deoxyguanosine adducts in human rectal tissue: a randomised clinical trial. *Br J Nutr.* 2015;114:220–30.
53. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS ONE.* 2010;5:e10667.
54. Skeie G, Braaten T, Hjartåker A, Lentjes M, Amiano P, Jakszyn P, et al. Use of dietary supplements in the European Prospective Investigation into Cancer and Nutrition calibration study. *Eur J Clin Nutr.* 2009;63:S226–38.

## ACKNOWLEDGEMENTS

The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The coordination of EPIC is financially supported by

International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology, ICO (Spain); Swedish Cancer Society, Swedish Research Council, Region Skåne and Region Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom). VF is supported by the Cancer Prevention and Research Institute of Texas (CPRIT) Rising Stars Award (Grant ID RR200056). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

## AUTHOR CONTRIBUTIONS

Conception and design: MJ, EKA, Acquisition and interpretation of data: all authors; Performed analyses: EKA, MJ, Drafted the paper: EKA, AJC, ER, VF, PJ, HF, DJH; Critically revised paper: all authors; Approved of final submission: all authors.

## FUNDING

Internal funds of the IARC were used to support these analyses.

## COMPETING INTERESTS

The authors declare no competing interests.

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Ethical approval was obtained from the IARC Ethical Committee and from local ethics committees pertaining to each EPIC center. All the participants provided written informed consent to enter the cohort.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41416-023-02164-7>.

**Correspondence** and requests for materials should be addressed to Mazda Jenab.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

<sup>1</sup>Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France. <sup>2</sup>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. <sup>3</sup>Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. <sup>4</sup>Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. <sup>5</sup>Cancer Biology and Therapeutics Group (CBT), Conway Institute, School of Biomolecular and Biomedical Science (SBBS), University College Dublin, Dublin, Ireland. <sup>6</sup>Centre de Recherche en Épidémiologie et Santé des Populations, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. <sup>7</sup>Institut Gustave Roussy, Villejuif, France. <sup>8</sup>Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. <sup>9</sup>Blanquerna School of Health Sciences, Ramon Llull University, Barcelona, Spain. <sup>10</sup>Department of Public Health,

Aarhus University, Aarhus, Denmark. <sup>11</sup>Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. <sup>12</sup>Danish Cancer Society Research Center, Copenhagen, Denmark. <sup>13</sup>Department of Public Health, Section of Environmental Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>14</sup>Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Florence, Italy. <sup>15</sup>Division of Cancer Epidemiology, German Cancer research Center (DKFZ), Heidelberg, Germany. <sup>16</sup>Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. <sup>17</sup>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany. <sup>18</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. <sup>19</sup>German Center for Diabetes Research (DZD), Neuherberg, Germany. <sup>20</sup>Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence, Italy. <sup>21</sup>Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian, 120133 Milano, Italy. <sup>22</sup>Internal Medicine and Clinical Nutrition Unit, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy. <sup>23</sup>Hyblean Association for Epidemiological Research, AIRE-ONLUS, 97100 Ragusa, Italy. <sup>24</sup>Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. <sup>25</sup>Unit of Epidemiology, Regional Health Service, ASL TO3 Grugliasco, TO, Italy. <sup>26</sup>Former senior scientist, Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands. <sup>27</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. <sup>28</sup>Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. <sup>29</sup>Escuela Andaluza de Salud Pública (EASP), Granada, Spain. <sup>30</sup>Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. <sup>31</sup>Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. <sup>32</sup>Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. <sup>33</sup>Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain. <sup>34</sup>Biodonostia Health Research Institute, Epidemiology and Public Health Area, San Sebastián, Spain. <sup>35</sup>Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. <sup>36</sup>Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia. <sup>37</sup>Navarra Public Health Institute, Pamplona, Spain. <sup>38</sup>Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. <sup>39</sup>Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden. <sup>40</sup>Department of Radiation Sciences, Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden. <sup>41</sup>Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. ✉email: jenabm@iacr.who.int